MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics today announced surveillance data demonstrating potency of the Company’s lead antibiotic product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide, against a broad spectrum of gram-positive bacteria prevalent in recent years. The surveillance data also confirmed that the susceptibility profile of dalbavancin has not changed since surveillance studies were first initiated over a decade ago.